# US 2026/0306616 A1 · Spike Protein Based Genetic Vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0306616 A1
- Document ID: US20260306616A1
- Status: Published application
- Kind: A1
- Application number: 19/638,377
- Filed: 2026-04-03
- Published: 2026-10-08
- Earliest claimed: 2025-04-04
- Assignees: University of Maryland, Baltimore
- Applicants: University of Maryland, Baltimore
- Inventors: Syed Saif Hasan; Suruchi Singh
- Web page: https://patentgrep.com/patent/US20260306616A1

## CPC

- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61P 31/14: for RNA viruses
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/575: {humoral response}
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are genetic vaccines and immunogenic constructs and methods of use effective to elicit immune responses against a coronavirus. The genetic vaccines and immunogenic constructs encode or comprise coronaviral spike tail peptides with one or two substitutions in the coatomer dibasic motif. Also provided are plasmids constructed to produce mRNAs for use in the genetic vaccines.

## Claims

### Claim 1

An immunogenic construct, comprising:
a coronavirus spike protein with at least one substitution therein.

### Claim 2 (depends on 1)

The immunogenic construct of claim 1, wherein the coronavirus spike protein comprises a substitution at one or both of the spike tail dibasic motif residues 1269Lys-Leu-His1271.

### Claim 3 (depends on 2)

The immunogenic construct of claim 2, wherein the substitution is 1269Lys-Leu-Lys1271 or 1269Ala-Leu-Ala.

### Claim 4 (depends on 1)

The immunogenic construct of claim 1, wherein the coronavirus spike protein comprises at least one sequence selected from the group consisting of GVALAYT (SEQ ID NO: 2), GVKLKYT (SEQ ID NO: 3), PHAVAVH (SEQ ID NO: 7), PHKVKVH (SEQ ID NO: 8), VEAIAIQ (SEQ ID NO: 9), VEKIKI (SEQ ID NO: 10), FEAVAVQ (SEQ ID NO: 11), and FEKVKVQ (SEQ ID NO: 12).

### Claim 5 (depends on 1)

The immunogenic construct of claim 1, wherein the coronavirus is a severe acute respiratory coronavirus 2 (SARS-CoV-2), a Middle East respiratory syndrome coronavirus (MERS-CoV), a human coronavirus 229E (HCoV 229E), or a human coronavirus NL63 (HCoV NL63).

### Claim 6 (depends on 1)

An immunological composition comprising the immunogenic construct of claim 1 and an immunologically acceptable excipient or adjuvant.

### Claim 7 (depends on 6)

A method for eliciting an immune response against a coronavirus in a subject in need thereof, comprising:
administering to the subject an amount of the immunological composition of claim 6 effective to elicit a protective antibody response.

### Claim 8

A plasmid, comprising:
a nucleic acid sequence that encodes an mRNA for a mutated coronavirus spike; and
a promoter operably linked to the nucleic acid sequence that regulates expression of the mRNA.

### Claim 9 (depends on 8)

The plasmid of claim 8, wherein the mRNA encodes at least one protein with a sequence selected from the group consisting of SEQ ID NOS: 2, 3, 7, 8, 9, 10, 11, and 12.

### Claim 10 (depends on 8)

The plasmid of claim 8, wherein the coronavirus is a severe acute respiratory coronavirus 2 (SARS-CoV-2), a Middle East respiratory syndrome coronavirus (MERS-CoV), a human coronavirus 229E (HCoV 229E), or a human coronavirus NL63 (HCoV NL63).

### Claim 11

A genetic vaccine, comprising:
a mRNA that encodes a mutated spike protein, wherein said protein, when produced in a recipient of the vaccine, elicits a protective immune response against a coronavirus.

### Claim 12 (depends on 11)

The genetic vaccine of claim 11, wherein the spike protein has a substitution at one or both of the spike tail dibasic motif residues 1269Lys-Leu-His1271.

### Claim 13 (depends on 12)

The genetic vaccine of claim 12, wherein the substitution is 1269Lys-Leu-Lys1271 or 1269Ala-Leu-Ala.

### Claim 14 (depends on 11)

The genetic vaccine of claim 11, wherein the mRNA encodes at least one spike protein sequence selected from the group consisting of GVALAYT (SEQ ID NO: 2), GVKLKYT (SEQ ID NO: 3), PHAVAVH (SEQ ID NO: 7), PHKVKVH (SEQ ID NO: 8), VEAIAIQ (SEQ ID NO: 9), VEKIKI (SEQ ID NO: 10), FEAVAVQ (SEQ ID NO: 11), and FEKVKVQ (SEQ ID NO: 12).

### Claim 15 (depends on 11)

The genetic vaccine of claim 11, wherein the coronavirus is a severe acute respiratory coronavirus 2 (SARS-CoV-2), a Middle East respiratory syndrome coronavirus (MERS-CoV), a human coronavirus 229E (HCoV 229E), or a human coronavirus NL63 (HCoV NL63).

### Claim 16 (depends on 11)

A method for preventing an onset of a coronaviral infection in a subject, comprising:
inoculating the subject with a first dose of the genetic vaccine of claim 11 effective to elicit anti-coronaviral antibody production in the subject.

### Claim 17 (depends on 16)

The method of claim 16, further comprising administering to the subject at least a second dose of the genetic vaccine.

### Claim 18 (depends on 16)

The method of claim 16, wherein the coronaviral infection is a severe acute respiratory coronavirus 2 infection.

### Claim 19

A genetic vaccine directed against a severe acute respiratory coronavirus 2, comprising:
a mRNA that encodes a mutated spike protein with a sequence comprising GVALAYT (SEQ ID NO: 2) or GVKLKYT (SEQ ID NO: 3) or a combination thereof.
